Showing results (1-10 of 486) with videos related to
Sort By:
Pageof 49
Current Cancer Drug Targets|August 22, 2002
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecanRon H J Mathijssen, Walter J Loos, Jaap Verweij, et al.Journal of the National Cancer Institute|August 22, 2002
Effects of St. John's wort on irinotecan metabolismRon H J Mathijssen, Jaap Verweij, Peter de Bruijn, et al.Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|January 22, 2011
Drug transporters of platinum-based anticancer agents and their clinical significanceHerman Burger, Walter J Loos, Karel Eechoute, et al.Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 3, 2003
Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detectionFloris A de Jong, Ron H J Mathijssen, Peter de Bruijn, et al.Nature Reviews. Clinical Oncology|March 26, 2014
Determining the optimal dose in the development of anticancer agentsRon H J Mathijssen, Alex Sparreboom, Jaap VerweijClinical Pharmacology and Therapeutics|December 14, 2004
Mechanism-based models for topotecan-induced neutropeniaFrédéric Léger, Walter J Loos, Roland Bugat, et al.The Oncologist|September 4, 2007
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?Ron H J Mathijssen, Floris A de Jong, Walter J Loos, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic studyFrederike K Engels, Walter J Loos, Jessica M van der Bol, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2010
Drug transporters and imatinib treatment: implications for clinical practiceKarel Eechoute, Alex Sparreboom, Herman Burger, et al.The Oncologist|August 2, 2006
Complementary and alternative medicine during cancer treatment: beyond innocenceMetin Tascilar, Floris A de Jong, Jaap Verweij, et al.Pageof 49